Myelodysplastic syndromes in adults;Syndromes myélodysplasiques de l'adulte

Presse Medicale

Volumn 36, Issue 3 II, 2007, Pages 481-491

  Beyne Rauzy, Odile ^a   Laurent, Guy ^b   Adoue, Daniel ^a  

^a Service de médecine interne et rhumatologie   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; COLONY STIMULATING FACTOR 1; CYCLOSPORIN A; CYTARABINE; DEFERASIROX; DEFEROXAMINE MESYLATE; GAMMA INTERFERON; IMMUNOLOGIC FACTOR; INTERLEUKIN 1; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; STEM CELL FACTOR; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CYTOGENETICS; CYTOPENIA; DISEASE CLASSIFICATION; HUMAN; KARYOTYPE; MICROENVIRONMENT; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PROGNOSIS; SHORT SURVEY; VASCULARIZATION; WORLD HEALTH ORGANIZATION;

EID: 34047224044     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2006.10.019     Document Type: Short Survey

References (20)

1. Claessens Y.E., and Fontenay-Roupie M. Physiopathologie des syndromes myélodysplasiques. Pathol Biol 50 (2002) 261-267
2. Nisse C., and Fenaux P. Epidémiologie et facteurs étiologiques des syndromes myélodysplasiques. Hématologie. 3 (1997) 431-438
3. Lessard M., Gervais C., and Struski S. Anomalies chromosomiques dans les syndromes myélodysplasiques secondaires et les leucémies. Pathol Biol 51 (2003) 356-365
4. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
5. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Ann Oncol 10 (1999) 1419-1432
6. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
7. Fenaux P., Morel P., and Lai J.L. Cytogenetics of myelodysplastic syndromes. Semin Hematol 33 (1996) 127-138
8. e congrès français de médecine interne, Tours 9-11 Décembre 2004. Rev. Med Int. 25 Supp4 (2004) S377
9. Aul C., Gattermann N., Heyll A., Germing U., Derigs G., and Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6 (1992) 52-59
10. Sole F., Luno E., Sanzo C., Espinet B., Sanz G.F., Cervera J., et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90 (2005) 1168-1178
11. th American Society of Hematology Annual Meeting, Atlanta, Georgia, 10-13 December 2005. Blood 106 (2005) 232a
12. Claessens Y.E., Park S., Dubart-Kupperschmitt A., Mariot V., Garrido C., Chretien S., et al. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood 105 (2005) 4035-4042
13. Merchav S., Wagemaker G., Souza L.M., and Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 5 (1991) 340-346
14. Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., and Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102 (1998) 1314-1322
15. Cutler C.S., Lee S.J., Greenberg P., Deeg H.J., Perez W.S., Anasetti C., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004) 579-585
16. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120 (2003) 1037-1046
17. Mannone L., Gardin C., Quarre M.C., Bernard J.F., Vassilieff D., Ades L., et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol. 133 (2006) 513-519
18. Bouscary D., Legros L., Tulliez M., Dubois S., Mahe B., Beyne-Rauzy O., et al. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol 131 (2005) 609-618
19. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
20. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465